- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01531257
Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients (Mini-Kidney)
Chronic Allograft Nephropathy (CAN)/Interstitial fibrosis and Tubular Atrophy (IFTA) is responsible for most kidney transplant failures. CAN/IFTA on a 3 month kidney biopsy strongly predicts graft survival long term. CAN/IFTA remains a vexing problem for clinicians because current monitoring tools, namely the serum creatinine concentration, are not sensitive to early changes in glomerular filtration rate (GFR) or to histologic damage.
Despite advances in prevention of acute rejection (AR), it is still a significant and potentially devastating complication of solid organ transplantation. One strategy to reduce the risk of rejection is to perform kidney biopsies to detect subclinical acute rejection (SCAR) and treat to prevent progression to rejection. There is evidence that treating SCAR can prevent further immune mediated injury to the kidney, a precursor to CAN/IFTA.
Kidney biopsies provide better information but are limited due to safety concerns, patient preference and cost issues. Better, early and less invasive markers of CAN/IFTA will allow early intervention as well as improved graft and better patient outcomes.
This study seeks to validate specific proteogenomic biomarker panels for AR and CAN/IFTA in a prospective blood, urine and kidney tissue monitoring study of kidney transplant recipients who will be scheduled for standard of care biopsies.
Study Overview
Status
Detailed Description
This is a single-center sample study. A total number of 1000 subjects will be consented and enrolled at Northwestern University Transplant clinic at the time of kidney biopsy. At our clinic, protocol biopsy may be performed at 3 months, 12 months , 24 months or any other time the doctor feels necessary post transplant in all kidney recipients. Kidney transplant recipients may also go under "for cause" biopsy procedure at any time point before/after or in between these protocol biopsy time points. Such causes of biopsy include increase in serum creatinine level, decrease in urine output, and/or pain at graft site.
Full blood tube set, urine sample for proteomics and flow cytometry of urinary sediment, and an extra core kidney biopsy tissue for gene expression profiling will be collected from subjects at the time of any biopsies obtained during the study course. These specimen samples will be sent to Rules-Based Medicine (RBM) for proteomic analysis. Whole genome expression profiling will be done using Affymetrix GeneChips at The Scripps Research Institute.
We estimate that we will find at least 500 subjects with diagnostic CAN/IFTA histology (Banff 1-2) between the 3 months and 12 months post transplant protocol biopsies based on a 50% incidence in the literature and our own experience. We also estimate that there will be 10% (10 subjects) incidence of clinical rejection by the end of 12 months identified initially by an acute rise in the serum creatinine and confirmed by a biopsy. Lastly, we estimate a 10% (10 subjects) incidence of subclinical acute rejection with stable renal function detected by the protocol kidney biopsies.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Jairo Chavez, BA
- Email: jairo.chavez@northwestern.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Jairo Chavez
-
Contact:
- Jairo Chavez, BA
- Email: jairo.chavez@northwestern.edu
-
Contact:
- Jairo
-
Principal Investigator:
- Sook H Park, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female recipients of all races, ≥18 years of age.
- Patients undergoing primary or subsequent deceased-donor or living donor kidney transplantation.
- Subject and/or guardian must be able to provide informed consent.
- Subject and/or guardian must be able to comply with the study protocol.
Exclusion Criteria:
- Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant.
- Recipients of previous non-renal solid organ and/or islet cell transplantation.
- Infection with HIV.
- Inability or unwillingness of a participant and/or guardian to provide informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Kidney Transplant Recipients
The intention of our biomarker panel is to be broadly applicable to all patients with a kidney transplant with the assumption that there are common underlying molecular mechanisms of AR and CAN/IFTA that can be detected hopefully at early stages of disease.
We therefore want to validate and test our biomarker panel in a broad collection of patient types.
We chose not to include patients with dual organ transplants so that we could isolate the molecular signal we are studying.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gene Expression Profiling
Time Frame: At time of any protocol or for-cause kidney biopsy, up to 10 years post transplant.
|
Full blood tube set, urine sample for proteomics and flow cytometry of urinary sediment, and an extra core kidney biopsy tissue for gene expression profiling will be collected from subjects at the time of any biopsies obtained during the study course.
Whole genome expression profiling will be done using Affymetrix GeneChips at The Scripps Research Institute.
|
At time of any protocol or for-cause kidney biopsy, up to 10 years post transplant.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sook H Park, MD, Northwestern University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU 25946
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Rejection (AR) of Transplanted Kidney
-
Hospital Vall d'HebronCompletedInfection | Intestinal Microbiota | Complication of Transplanted Liver | Acute Rejection of Liver TransplantSpain
-
Mark StegallMillennium Pharmaceuticals, Inc.TerminatedDisorder of Transplanted KidneyUnited States
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityCompletedDisorder of Transplanted KidneyNorway
-
NovartisCompletedPrevention of Acute Rejection After Kidney Transplantation
-
NovartisCompletedPrevention of Acute Rejection After Kidney Transplantation
-
University of ManitobaCanadian Institutes of Health Research (CIHR); Canadian National Transplant...RecruitingKidney Transplant; Complications | Rejection of Renal TransplantAustralia, Canada
-
Martina SesterCompletedKidney Transplantation | Acute Graft RejectionGermany
-
Seoul National University HospitalRecruitingKidney Transplantation | Rejection Acute RenalKorea, Republic of
-
University of MinnesotaRecruitingRejection of Kidney AllograftUnited States
-
Fundación Pública Andaluza para la Investigación...Sociedad Andaluza de Trasplantes de Organos y TejidosCompletedRenal Transplant Rejection | Other Complication of Kidney TransplantSpain